Table 1.
Baseline Cohort Characteristics Stratified by HIV RNA Viral Load Suppression Over Follow-Up Among Injection Drug Users Initiating Therapy in Vancouver, Canada (n=240)
| Characteristic | No viral suppression 104 (43.3) | >0 viral suppression 136 (56.7) | Odds ratio | 95% Confidence interval | p Value |
|---|---|---|---|---|---|
| Homelessnessa | |||||
| No | 87 (83.7) | 112 (82.4) | 1.00 | ||
| Yes | 17 (16.3) | 24 (17.6) | 1.10 | 0.55–2.17 | 0.791 |
| Age | |||||
| Median (IQR) | 35.8 (28.2–43.3) | 37.2 (31.2–43.1) | 1.01 | 1.00–1.01 | 0.083 |
| Gender | |||||
| Male | 53 (51.0) | 75 (55.1) | 1.00 | ||
| Female | 51 (49.0) | 61 (44.9) | 0.85 | 0.51–1.41 | 0.520 |
| Aboriginal ancestry | |||||
| No | 57 (54.8) | 72 (52.9) | 1.00 | ||
| Yes | 47 (45.2) | 64 (47.1) | 1.08 | 0.65–1.80 | 0.774 |
| Educationa | |||||
| ≥ High school diploma | 62 (59.6) | 84 (61.8) | 1.00 | ||
| < High school diploma | 42 (40.4) | 52 (38.2) | 0.91 | 0.54–1.54 | 0.735 |
| Employmenta | |||||
| No | 102 (98.1) | 127 (93.3) | 1.00 | ||
| Yes | 2 (1.9) | 9 (6.6) | 3.61 | 0.76–17.10 | 0.085 |
| Illicit drug usea | |||||
| None | 9 (8.7) | 12 (8.8) | 1.00 | ||
| Any illicit drug use | 11 (10.6) | 15 (11.0) | 1.02 | 0.32–3.27 | 0.970 |
| Any injection drug | 84 (80.8) | 109 (80.1) | 0.97 | 0.39–2.42 | 0.953 |
| Sex trade participationa | |||||
| No | 83 (79.8) | 116 (85.3) | 1.00 | ||
| Yes | 21 (20.2) | 20 (14.7) | 0.68 | 0.35–1.34 | 0.263 |
| Incarcerationa | |||||
| No | 75 (72.1) | 111 (81.6) | 1.00 | ||
| Yes | 29 (27.9) | 25 (18.4) | 0.58 | 0.32–1.07 | 0.081 |
| HIV MD experience | |||||
| ≥6 patients | 87 (83.7) | 117 (86.0) | 1.00 | ||
| <6 patients | 17 (16.3) | 19 (14.0) | 0.83 | 0.41–1.69 | 0.610 |
| Year of ART initiation | |||||
| Median (IQR) | 1998 (1995–2001) | 1999 (1997–2001) | 1.00 | 0.98–1.01 | 0.662 |
| Plasma HIV-1 RNA | |||||
| Median (IQR) | 4.7 (4.3–5.1) | 3.6 (2.6–4.6) | 0.83 | 0.79–0.87 | <0.001 |
| CD4 cell count | |||||
| Median (IQR) | 2.7 (1.5–3.9) | 2.6 (1.7–3.5) | 1.01 | 0.98–1.04 | 0.709 |
a
Refers to the 6-month period prior to the baseline interview.
IQR, interquartile range; ART, antiretroviral therapy.